Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years.~* Must have received prior therapy for their WM and have relapsed or refractory WM. Any number of prior therapies is acceptable.~* Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level of \> 2 times the upper limit of each institution's normal value is required and over 10% of lymphoplasmacytic cells in the bone marrow.~* ECOG Performance Status (PS) 0, 1, or 2.~* The following laboratory values obtained 14 days prior to registration~* ANC \>= 1 x109/L~* PLT \>= 75 x109/L~* Total bilirubin ≤ 2.0 mg/dL (If total is elevated check direct and if normal patient is eligible.)~* AST \<= 3 x upper limit of normal (ULN)~* Creatinine \<= 2 x ULN~* Ability to provide informed consent.~* Life expectancy \>= 12 weeks.~Exclusion Criteria:~* Uncontrolled infection.~* Other active malignancies.~* CNS involvement.~* Cytotoxic chemotherapy ≤ 3 weeks, or biologic therapy ≤ 2 weeks, or corticosteroids ≤ 2 weeks, prior to registration. Patients may be receiving chronic corticosteroids if they are being given for disorders other than WM such as auto-immune diseases. Plasmapheresis is not considered as an active therapy and can be used at the physician's discretion.~* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational.~* Any of the following:~* Pregnant women~* Nursing women~* Men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device (IUD), or abstinence, etc.)~* Known to be HIV positive.~* Radiation therapy ≤ 2 weeks prior to registration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Perifosine (Type: EXPERIMENTAL): Patients will receive perifosine orally at 150 mg daily after food for 28-d cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).